1. Bristol-Myers Squibb. Coumadin (wafarin sodium) prescribing information. 2017.
http://packageinserts.bms.com/pi/pi_coumadin.pdf
. Accessed 2 Feb 2018.
2. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.
3. Bristol-Myers Squibb, Pfizer EEIG. EU summary of product characteristics: Eliquis (apixaban tablets). 2018.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
. Accessed 8 Apr 2019.
4. Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. 2018.
http://packageinserts.bms.com/pi/pi_eliquis.pdf
. Accessed 14 Jun 2018.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.